Paper28096293
The role of MDM2 and MDM4 in breast cancer development and prevention.
Haupt S and 5 others. J Mol Cell Biol, 2017. Cited by 68 papers, by iCite.
Cite this record
ConductScience Library. The role of MDM2 and MDM4 in breast cancer development and prevention. Papers, record 28096293. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28096293
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Nuclear Proteins | Major topic |
| Proto-Oncogene Proteins c-mdm2 | Major topic |
| Animals | |
| Female | |
| Humans | |
| Morphogenesis | |
| Stress, Physiological | |
| Tumor Suppressor Protein p53 |
Source PubMed
References88
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 7477327 | Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. | Nature | 1995 | https://conductscience.org/library/papers/7477327 | PubMed |
| 2 | 17363597 | A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells. | Cancer Res | 2007 | https://conductscience.org/library/papers/17363597 | PubMed |
| 3 | 9811461 | Delayed involution of the mammary epithelium in BALB/c-p53null mice. | Oncogene | 1998 | https://conductscience.org/library/papers/9811461 | PubMed |
| 4 | 24236052 | MDM2 promotes invasion and metastasis in invasive ductal breast carcinoma by inducing matrix metalloproteinase-9. | PLoS One | 2013 | https://conductscience.org/library/papers/24236052 | PubMed |
| 5 | 22349818 | Coordinate regulation of estrogen receptor β degradation by Mdm2 and CREB-binding protein in response to growth signals. | Oncogene | 2013 | https://conductscience.org/library/papers/22349818 | PubMed |
| 6 | 11306511 | Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. | Cancer Res | 2001 | https://conductscience.org/library/papers/11306511 | PubMed |
| 7 | 17996864 | Altered mammary gland development in the p53+/m mouse, a model of accelerated aging. | Dev Biol | 2008 | https://conductscience.org/library/papers/17996864 | PubMed |
| 8 | 12150820 | Alternative and aberrant splicing of MDM2 mRNA in human cancer. | Cancer Cell | 2002 | https://conductscience.org/library/papers/12150820 | PubMed |
| 9 | 24292333 | Subcellular localization of Mdm2 expression and prognosis of breast cancer. | Int J Clin Oncol | 2014 | https://conductscience.org/library/papers/24292333 | PubMed |
| 10 | 17080308 | MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling. | Breast Cancer Res Treat | 2007 | https://conductscience.org/library/papers/17080308 | PubMed |
| 11 | 24525025 | ARF tumor suppression in the nucleolus. | Biochim Biophys Acta | 2014 | https://conductscience.org/library/papers/24525025 | PubMed |
| 12 | 10227293 | p63 is a p53 homologue required for limb and epidermal morphogenesis. | Nature | 1999 | https://conductscience.org/library/papers/10227293 | PubMed |
| 13 | 17417639 | Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. | Nat Genet | 2007 | https://conductscience.org/library/papers/17417639 | PubMed |
| 14 | 21454711 | Mutant p53 disrupts MCF-10A cell polarity in three-dimensional culture via epithelial-to-mesenchymal transitions. | J Biol Chem | 2011 | https://conductscience.org/library/papers/21454711 | PubMed |
| 15 | 20679392 | The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. | Genes Dev | 2010 | https://conductscience.org/library/papers/20679392 | PubMed |
| 16 | 21316605 | The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. | Cancer Cell | 2011 | https://conductscience.org/library/papers/21316605 | PubMed |
| 17 | 9087426 | Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. | Genes Dev | 1997 | https://conductscience.org/library/papers/9087426 | PubMed |
| 18 | 24739573 | Unravelling mechanisms of p53-mediated tumour suppression. | Nat Rev Cancer | 2014 | https://conductscience.org/library/papers/24739573 | PubMed |
| 19 | 7891224 | mdm2 gene alterations and mdm2 protein expression in breast carcinomas. | J Pathol | 1995 | https://conductscience.org/library/papers/7891224 | PubMed |
| 20 | 23150756 | The Many Faces of MDM2 Binding Partners. | Genes Cancer | 2012 | https://conductscience.org/library/papers/23150756 | PubMed |
Cited by54
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 68 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42678985 | Association of MDM2 rs2279744 and rs937282 polymorphisms with breast cancer susceptibility and circulating MDM2 and p53 levels in Bangladeshi women: A case-control study. | PLoS One | 2026 | https://conductscience.org/library/papers/42678985 | PubMed |
| 41834461 | Exploring the Relationship Between MDM4 Gene Polymorphisms (rs1380576 and rs4245739) and Breast Cancer Susceptibility in Bangladesh: A Case-Control Study. | J Clin Lab Anal | 2026 | https://conductscience.org/library/papers/41834461 | PubMed |
| 40949156 | Emerging opportunities to treat drug-resistant breast cancer: Discovery of novel small-molecule inhibitors against different targets. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40949156 | PubMed |
| 40932605 | Molecular signatures of breast cancer in the Iranian population: a review of cell growth and cell cycle regulators. | J Cancer Res Clin Oncol | 2025 | https://conductscience.org/library/papers/40932605 | PubMed |
| 40308267 | Computational identification of potential natural terpenoid inhibitors of MDM2 for breast cancer therapy: molecular docking, molecular dynamics simulation, and ADMET analysis. | Front Chem | 2025 | https://conductscience.org/library/papers/40308267 | PubMed |
| 40251552 | CCT8 drives colorectal cancer progression via the RPL4-MDM2-p53 axis and immune modulation. | BMC Med Genomics | 2025 | https://conductscience.org/library/papers/40251552 | PubMed |
| 40191734 | Targeting MDM2-p53 interaction for breast cancer therapy. | Oncol Res | 2025 | https://conductscience.org/library/papers/40191734 | PubMed |
| 39940844 | Pharmacological Inhibition of MDM2 Induces Apoptosis in p53-Mutated Triple-Negative Breast Cancer. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/39940844 | PubMed |
| 39567687 | Normal breast tissues harbour rare populations of aneuploid epithelial cells. | Nature | 2024 | https://conductscience.org/library/papers/39567687 | PubMed |
| 39479021 | Roles of lncRNAs related to the p53 network in breast cancer progression. | Front Oncol | 2024 | https://conductscience.org/library/papers/39479021 | PubMed |
| 39329452 | SNRPB2 promotes triple-negative breast cancer progression by controlling alternative splicing of MDM4 pre-mRNA. | Cancer Sci | 2024 | https://conductscience.org/library/papers/39329452 | PubMed |
| 39234815 | FGF12 Positively Regulates Keratinocyte Proliferation by Stabilizing MDM2 and Inhibiting p53 Activity in Psoriasis. | Adv Sci (Weinh) | 2024 | https://conductscience.org/library/papers/39234815 | PubMed |
| 39000582 | HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39000582 | PubMed |
| 38354236 | Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo. | Sci Adv | 2024 | https://conductscience.org/library/papers/38354236 | PubMed |
| 37804415 | Death-associated protein kinase 1 phosphorylates MDM2 and inhibits its protein stability and function. | Arch Pharm Res | 2023 | https://conductscience.org/library/papers/37804415 | PubMed |
| 37374977 | Effect of Borrelia burgdorferi on the Expression of miRNAs in Breast Cancer and Normal Mammary Epithelial Cells. | Microorganisms | 2023 | https://conductscience.org/library/papers/37374977 | PubMed |
| 37314603 | MDM2- an indispensable player in tumorigenesis. | Mol Biol Rep | 2023 | https://conductscience.org/library/papers/37314603 | PubMed |
| 37264344 | Effect of Smilax spp. and Phellinus linteus combination on cytotoxicity and cell proliferation of breast cancer cells. | BMC Complement Med Ther | 2023 | https://conductscience.org/library/papers/37264344 | PubMed |
| 37217945 | S100A6 inhibits MDM2 to suppress breast cancer growth and enhance sensitivity to chemotherapy. | Breast Cancer Res | 2023 | https://conductscience.org/library/papers/37217945 | PubMed |
| 36831624 | Potential Impact of PI3K-AKT Signaling Pathway Genes, KLF-14, MDM4, miRNAs 27a, miRNA-196a Genetic Alterations in the Predisposition and Progression of Breast Cancer Patients. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36831624 | PubMed |
Genes28
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28096293
GET https://conductscience.org/api/papers/v1/28096293/references?page=2